|
US3896111A
(en)
|
1973-02-20 |
1975-07-22 |
Research Corp |
Ansa macrolides
|
|
US4237224A
(en)
|
1974-11-04 |
1980-12-02 |
Board Of Trustees Of The Leland Stanford Jr. University |
Process for producing biologically functional molecular chimeras
|
|
US4151042A
(en)
|
1977-03-31 |
1979-04-24 |
Takeda Chemical Industries, Ltd. |
Method for producing maytansinol and its derivatives
|
|
US4137230A
(en)
|
1977-11-14 |
1979-01-30 |
Takeda Chemical Industries, Ltd. |
Method for the production of maytansinoids
|
|
US4265814A
(en)
|
1978-03-24 |
1981-05-05 |
Takeda Chemical Industries |
Matansinol 3-n-hexadecanoate
|
|
US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
|
JPS5562090A
(en)
|
1978-10-27 |
1980-05-10 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS5566585A
(en)
|
1978-11-14 |
1980-05-20 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
|
JPS55164687A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
|
JPS55164685A
(en)
|
1979-06-08 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS55164686A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
US4309428A
(en)
|
1979-07-30 |
1982-01-05 |
Takeda Chemical Industries, Ltd. |
Maytansinoids
|
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
|
EP0028683A1
(en)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotic C-15003 PHO and production thereof
|
|
WO1981001145A1
(en)
|
1979-10-18 |
1981-04-30 |
Univ Illinois |
Hydrolytic enzyme-activatible pro-drugs
|
|
WO1982001188A1
(en)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
4,5-deoxymaytansinoide compounds and process for preparing same
|
|
US4450254A
(en)
|
1980-11-03 |
1984-05-22 |
Standard Oil Company |
Impact improvement of high nitrile resins
|
|
US4315929A
(en)
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
|
JPS57192389A
(en)
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
|
US4751180A
(en)
|
1985-03-28 |
1988-06-14 |
Chiron Corporation |
Expression using fused genes providing for protein product
|
|
US4935233A
(en)
|
1985-12-02 |
1990-06-19 |
G. D. Searle And Company |
Covalently linked polypeptide cell modulators
|
|
US5182368A
(en)
*
|
1986-06-13 |
1993-01-26 |
Ledbetter Jeffrey A |
Ligands and methods for augmenting B-cell proliferation
|
|
US5247069A
(en)
|
1986-06-13 |
1993-09-21 |
Oncogen |
Ligands and methods for augmenting B-cell proliferation
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
GB8705477D0
(en)
|
1987-03-09 |
1987-04-15 |
Carlton Med Prod |
Drug delivery systems
|
|
US5091513A
(en)
|
1987-05-21 |
1992-02-25 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
|
US5132405A
(en)
|
1987-05-21 |
1992-07-21 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
|
US4975278A
(en)
|
1988-02-26 |
1990-12-04 |
Bristol-Myers Company |
Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
|
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5151510A
(en)
|
1990-04-20 |
1992-09-29 |
Applied Biosystems, Inc. |
Method of synethesizing sulfurized oligonucleotide analogs
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US5264586A
(en)
|
1991-07-17 |
1993-11-23 |
The Scripps Research Institute |
Analogs of calicheamicin gamma1I, method of making and using the same
|
|
ZA932522B
(en)
|
1992-04-10 |
1993-12-20 |
Res Dev Foundation |
Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
|
|
US5397703A
(en)
|
1992-07-09 |
1995-03-14 |
Cetus Oncology Corporation |
Method for generation of antibodies to cell surface molecules
|
|
US6765087B1
(en)
|
1992-08-21 |
2004-07-20 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
|
ATE199392T1
(de)
|
1992-12-04 |
2001-03-15 |
Medical Res Council |
Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
|
|
WO1994025591A1
(en)
|
1993-04-29 |
1994-11-10 |
Unilever N.V. |
PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
|
|
FI961285L
(fi)
|
1993-10-01 |
1996-03-20 |
Immunex Corp |
CD40:n vasta-aineita
|
|
DE69433820T2
(de)
*
|
1993-12-23 |
2005-06-23 |
Immunex Corp., Seattle |
Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
|
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
|
GB9425060D0
(en)
|
1994-12-13 |
1995-02-08 |
Univ Birmingham |
Carcinoma treatment
|
|
US5675063A
(en)
|
1995-02-28 |
1997-10-07 |
Loyola University Of Chicago |
Immortalized rabbit hybridoma fusion partner
|
|
PT812206E
(pt)
|
1995-03-01 |
2002-11-29 |
Immunex Corp |
Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
|
EP1033406A4
(en)
*
|
1997-10-27 |
2005-03-09 |
Sumitomo Electric Industries |
INDUCER FOR THE PRODUCTION OF ANTIGEN-SPECIFIC ANTIBODY, EXPRESSION VECTOR CONTAINING THE GENE REQUIRED THEREFOR, AND METHOD FOR INDUCING THE PRODUCTION OF THE ANTIGEN-SPECIFIC ANTIBODY
|
|
US6051228A
(en)
|
1998-02-19 |
2000-04-18 |
Bristol-Myers Squibb Co. |
Antibodies against human CD40
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
KR100301796B1
(ko)
*
|
1998-10-01 |
2001-09-06 |
성재갑 |
면역억제능이 있는 항-씨디40 리간드 모노클로날 항체
|
|
US6680176B2
(en)
|
1999-05-17 |
2004-01-20 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Identification of candidate ligands which modulate antigen presenting cells
|
|
US20030118588A1
(en)
|
1999-05-22 |
2003-06-26 |
Linda Diehl |
Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
|
|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
|
MXPA02007473A
(es)
|
2000-02-01 |
2003-09-22 |
Tanox Inc |
Moleculas activadoras de celulas presentadoras de antigenos (apc) que se unen a cd40.
|
|
CA2406961A1
(en)
*
|
2000-04-19 |
2002-02-14 |
Tanox, Inc. |
Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions
|
|
US7063845B2
(en)
|
2000-04-28 |
2006-06-20 |
Gemini Science, Inc. |
Human anti-CD40 antibodies
|
|
JP5007409B2
(ja)
|
2000-05-08 |
2012-08-22 |
セルデックス リサーチ コーポレーション |
樹状細胞に対するヒトモノクローナル抗体
|
|
CA2658221C
(en)
|
2001-04-27 |
2012-11-27 |
Kyowa Kirin Co., Ltd. |
Anti-cd40 monoclonal antibody
|
|
JP4025881B2
(ja)
*
|
2001-04-27 |
2007-12-26 |
キリンファーマ株式会社 |
抗ｃｄ４０モノクローナル抗体
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20080199471A1
(en)
|
2002-03-01 |
2008-08-21 |
Bernett Matthew J |
Optimized cd40 antibodies and methods of using the same
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US8093357B2
(en)
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
AU2003217912A1
(en)
*
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
|
US7355008B2
(en)
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
CN1761746B
(zh)
*
|
2003-01-22 |
2016-03-23 |
罗氏格黎卡特股份公司 |
融合构建体及其用来生产Fc受体结合亲和性和效应子功能提高的抗体的用途
|
|
AU2004287879C1
(en)
*
|
2003-11-04 |
2011-05-26 |
Novartis Vaccines And Diagnostics, Inc. |
Antagonist anti-CD40 monoclonal antibodies and methods for their use
|
|
JP2007512846A
(ja)
|
2003-12-04 |
2007-05-24 |
ゼンコー・インコーポレイテッド |
増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
|
|
US20050136055A1
(en)
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
|
EP1707627B1
(en)
*
|
2003-12-25 |
2012-11-14 |
Kyowa Hakko Kirin Co., Ltd. |
Antagonistic anti-CD40 antibody mutant
|
|
BRPI0514068B8
(pt)
|
2004-08-04 |
2021-05-25 |
Applied Molecular Evolution Inc |
anticorpo anti-cd20, e, composição farmacêutica
|
|
US7462697B2
(en)
|
2004-11-08 |
2008-12-09 |
Epitomics, Inc. |
Methods for antibody engineering
|
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
|
JP2008528010A
(ja)
|
2005-01-31 |
2008-07-31 |
アブリンクス ナームローゼ フェンノートシャップ |
重鎖抗体の可変ドメイン配列を作出する方法
|
|
US20060257359A1
(en)
|
2005-02-28 |
2006-11-16 |
Cedric Francois |
Modifying macrophage phenotype for treatment of disease
|
|
AU2006230413B8
(en)
|
2005-03-31 |
2011-01-20 |
Xencor, Inc |
Fc variants with optimized properties
|
|
EP2312315A1
(en)
|
2005-05-18 |
2011-04-20 |
Novartis AG |
Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
|
|
AU2006247067B2
(en)
|
2005-05-18 |
2012-06-07 |
Novartis Ag |
Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling
|
|
JP5027804B2
(ja)
|
2005-05-26 |
2012-09-19 |
シアトル ジェネティクス，インコーポレーテッド |
ヒト化抗ｃｄ４０抗体およびその使用方法
|
|
US7429487B2
(en)
|
2005-07-05 |
2008-09-30 |
Epitomics, Inc. |
Fusion partner for production of monoclonal rabbit antibodies
|
|
WO2007041238A2
(en)
|
2005-09-29 |
2007-04-12 |
Stratagene California |
Methods of identification and use of gene signatures
|
|
WO2007053661A2
(en)
|
2005-11-01 |
2007-05-10 |
Novartis Ag |
Uses of anti-cd40 antibodies
|
|
EP1945260B1
(en)
*
|
2005-11-01 |
2012-10-24 |
Novartis AG |
Uses of anti-cd40 antibodies
|
|
KR101866623B1
(ko)
|
2005-11-28 |
2018-07-04 |
젠맵 에이/에스 |
재조합 １가 항체 및 그의 제조 방법
|
|
MX2008007140A
(es)
*
|
2005-12-09 |
2009-03-04 |
Seattle Genetics Inc |
Metodos para utilizar agentes de union a cd40.
|
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
US8691210B2
(en)
|
2006-10-19 |
2014-04-08 |
David M Spencer |
Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof
|
|
SG177168A1
(en)
|
2006-12-01 |
2012-01-30 |
Medarex Inc |
Human antibodies that bind cd22 and uses thereof
|
|
CN101605906A
(zh)
|
2006-12-14 |
2009-12-16 |
梅达雷克斯公司 |
结合cd70的人类抗体及其用途
|
|
CA2669412A1
(en)
*
|
2007-01-23 |
2008-07-31 |
Xencor, Inc. |
Optimized cd40 antibodies and methods of using the same
|
|
US20080241065A1
(en)
|
2007-03-27 |
2008-10-02 |
Benaron David A |
Systems and methods for the detection and analysis of in vivo circulating cells, entities, and nanobots
|
|
US8062864B2
(en)
|
2007-05-21 |
2011-11-22 |
Alderbio Holdings Llc |
Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
|
|
NZ601583A
(en)
|
2007-05-21 |
2013-08-30 |
Bristol Myers Squibb Co |
Novel rabbit antibody humanization methods and humanized rabbit antibodies
|
|
US20090238825A1
(en)
|
2007-05-21 |
2009-09-24 |
Kovacevich Brian R |
Novel rabbit antibody humanization methods and humanized rabbit antibodies
|
|
EP1997832A1
(en)
|
2007-05-29 |
2008-12-03 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies against Claudin-18 for treatment of cancer
|
|
CA2693053C
(en)
*
|
2007-05-30 |
2021-01-05 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
|
AU2009206506B2
(en)
|
2008-01-23 |
2013-01-10 |
Xencor, Inc. |
Optimized CD40 antibodies and methods of using the same
|
|
WO2010009346A2
(en)
|
2008-07-16 |
2010-01-21 |
Baylor Research Institute |
Hiv vaccine based on targeting maximized gag and nef to dendritic cells
|
|
JP2012501323A
(ja)
|
2008-08-29 |
2012-01-19 |
アカデミシュ ジーケンハウス ライデン ハー．オー．デー．エン． ルムク |
対象の腫瘍流入領域リンパ節へのｃｄ４０アゴニストの送達
|
|
EP2367849B1
(en)
|
2008-12-05 |
2017-11-01 |
ALS Therapy Development Institute |
Method for the treatment of neurodegenerative diseases
|
|
BRPI1009455A2
(pt)
|
2009-03-10 |
2016-03-01 |
Baylor Res Inst |
anticorpos anti-c40 e usos dos mesmos
|
|
WO2010121231A1
(en)
|
2009-04-18 |
2010-10-21 |
Genentech, Inc. |
Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
|
|
JP5694921B2
(ja)
|
2009-04-20 |
2015-04-01 |
協和発酵キリン株式会社 |
アミノ酸変異が導入されたＩｇＧ２を有する抗体
|
|
AU2011223789A1
(en)
|
2010-03-01 |
2012-09-20 |
Caris Life Sciences Switzerland Holdings Gmbh |
Biomarkers for theranostics
|
|
US20130108623A1
(en)
*
|
2010-03-29 |
2013-05-02 |
Zymeworks Inc |
Antibodies with Enhanced or Suppressed Effector Function
|
|
EP2796467B1
(en)
|
2010-03-31 |
2018-03-28 |
Boehringer Ingelheim International GmbH |
Anti-CD40 antibodies
|
|
WO2011140828A1
(en)
|
2010-05-14 |
2011-11-17 |
The University Of Hong Kong |
Gep antibody and uses thereof
|
|
EP2600878A4
(en)
|
2010-08-04 |
2014-06-11 |
Univ Duke |
REGULATORY B-CELLS AND ITS USES
|
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
|
WO2012087928A2
(en)
|
2010-12-20 |
2012-06-28 |
The Rockefeller University |
Modulating agonistic tnfr antibodies
|
|
NO2699601T3
(enExample)
*
|
2011-04-21 |
2018-06-16 |
|
|
|
KR102037432B1
(ko)
|
2011-04-29 |
2019-11-27 |
아펙시젠, 인코포레이티드 |
항-cd40 항체 및 사용 방법
|
|
SG10201702015YA
(en)
|
2012-09-18 |
2017-04-27 |
Agency Science Tech & Res |
Grouping for classifying gastric cancer
|
|
CA2888763A1
(en)
|
2012-10-30 |
2014-05-08 |
Apexigen, Inc. |
Anti-cd40 antibodies and methods of use
|
|
US9209965B2
(en)
|
2014-01-14 |
2015-12-08 |
Microsemi Semiconductor Ulc |
Network interface with clock recovery module on line card
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
EP3180087B1
(en)
|
2014-08-12 |
2019-03-13 |
Alligator Bioscience AB |
Combination therapies with anti cd40 antibodies
|
|
AU2015358462A1
(en)
|
2014-12-04 |
2017-07-27 |
Bristol-Myers Squibb Company |
Combination of anti-CS1 and anti-PD1 antibodies to treat cancer (myeloma)
|
|
US20180223368A1
(en)
|
2015-03-18 |
2018-08-09 |
Memorial Sloan Ketteting Cancer Center |
Methods for diagnosing and treating follicular lymphoma
|
|
DK3294770T4
(da)
|
2015-05-12 |
2024-05-21 |
Hoffmann La Roche |
Terapeutiske og diagnostiske fremgangsmåder til cancer
|
|
PE20180315A1
(es)
|
2015-06-29 |
2018-02-09 |
Bristol Myers Squibb Co |
Anticuerpos para cd40
|
|
US20200079860A1
(en)
|
2015-08-06 |
2020-03-12 |
Memorial Sloan Kettering Cancer Center |
Methods and compositions for tumor therapy
|
|
CN110114089A
(zh)
|
2016-11-02 |
2019-08-09 |
埃派斯进有限公司 |
组合中的抗cd40抗体及其使用方法
|
|
WO2019143880A1
(en)
|
2018-01-19 |
2019-07-25 |
Dana-Farber Cancer Institute, Inc. |
Biomarkers predictive of anti-immune checkpoint response
|
|
JP2024523181A
(ja)
|
2021-06-03 |
2024-06-28 |
アペクシジェン アメリカ， インコーポレイテッド |
Ｃｄ－４０アゴニストを用いてがんを処置する方法
|
|
US20240336693A1
(en)
|
2021-08-10 |
2024-10-10 |
Apexigen, Inc. |
Biomarkers for cd40 agonist therapy
|